BRPI0718830A2 - Métodos para tratar anemia hemolítica - Google Patents
Métodos para tratar anemia hemolítica Download PDFInfo
- Publication number
- BRPI0718830A2 BRPI0718830A2 BRPI0718830-7A BRPI0718830A BRPI0718830A2 BR PI0718830 A2 BRPI0718830 A2 BR PI0718830A2 BR PI0718830 A BRPI0718830 A BR PI0718830A BR PI0718830 A2 BRPI0718830 A2 BR PI0718830A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- antibody
- patients
- compound
- eculizumab
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 195
- 208000007475 hemolytic anemia Diseases 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 164
- 230000000295 complement effect Effects 0.000 claims description 120
- 210000003743 erythrocyte Anatomy 0.000 claims description 117
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 110
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 75
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 75
- 230000009467 reduction Effects 0.000 claims description 69
- 230000000694 effects Effects 0.000 claims description 63
- 230000002949 hemolytic effect Effects 0.000 claims description 50
- 102000001554 Hemoglobins Human genes 0.000 claims description 48
- 108010054147 Hemoglobins Proteins 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 41
- 208000007536 Thrombosis Diseases 0.000 claims description 40
- 102000003951 Erythropoietin Human genes 0.000 claims description 39
- 108090000394 Erythropoietin Proteins 0.000 claims description 39
- 239000003146 anticoagulant agent Substances 0.000 claims description 39
- 229940105423 erythropoietin Drugs 0.000 claims description 39
- 208000005189 Embolism Diseases 0.000 claims description 38
- 210000003714 granulocyte Anatomy 0.000 claims description 37
- 102100031506 Complement C5 Human genes 0.000 claims description 35
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 claims description 35
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 33
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 31
- 229940127219 anticoagulant drug Drugs 0.000 claims description 29
- 108090000623 proteins and genes Chemical group 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 208000001435 Thromboembolism Diseases 0.000 claims description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 13
- 102000006395 Globulins Human genes 0.000 claims description 12
- 108010044091 Globulins Proteins 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 10
- 108010019673 Darbepoetin alfa Proteins 0.000 claims description 10
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 10
- 230000002785 anti-thrombosis Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 230000011132 hemopoiesis Effects 0.000 claims description 9
- 229940115115 aranesp Drugs 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 102000007079 Peptide Fragments Human genes 0.000 claims description 6
- 108010033276 Peptide Fragments Proteins 0.000 claims description 6
- 108091008103 RNA aptamers Proteins 0.000 claims description 6
- 101710181904 Venom factor Proteins 0.000 claims description 6
- 230000000781 anti-lymphocytic effect Effects 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 6
- JJGZGELTZPACID-OTLJHNKQSA-N chloropeptin II Chemical compound N([C@@H]1CC=2C3=CC=C(C=C3NC=2)C=2C=C3C=C(C=2O)OC2=CC=C(C=C2)C[C@H](N(C([C@@H](C=2C=C(Cl)C(O)=C(Cl)C=2)NC(=O)[C@@H]3NC(=O)[C@@H](C=2C=C(Cl)C(O)=C(Cl)C=2)NC1=O)=O)C)C(=O)N[C@@H](C(O)=O)C=1C=CC(O)=CC=1)C(=O)C(=O)C1=CC(Cl)=C(O)C(Cl)=C1 JJGZGELTZPACID-OTLJHNKQSA-N 0.000 claims description 6
- 108010029904 complestatin Proteins 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- JJGZGELTZPACID-UHFFFAOYSA-N isocomplestatin Natural products O=C1NC(C=2C=C(Cl)C(O)=C(Cl)C=2)C(=O)NC2C(=O)NC(C=3C=C(Cl)C(O)=C(Cl)C=3)C(=O)N(C)C(C(=O)NC(C(O)=O)C=3C=CC(O)=CC=3)CC(C=C3)=CC=C3OC(C=3O)=CC2=CC=3C(C=C2NC=3)=CC=C2C=3CC1NC(=O)C(=O)C1=CC(Cl)=C(O)C(Cl)=C1 JJGZGELTZPACID-UHFFFAOYSA-N 0.000 claims description 6
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 claims description 6
- 229950009865 nafamostat Drugs 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 239000003998 snake venom Substances 0.000 claims description 6
- 229960003284 iron Drugs 0.000 claims description 5
- 239000003001 serine protease inhibitor Substances 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 102000016550 Complement Factor H Human genes 0.000 claims description 4
- 108010053085 Complement Factor H Proteins 0.000 claims description 4
- 239000003173 antianemic agent Substances 0.000 claims description 4
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims description 4
- 230000001314 paroxysmal effect Effects 0.000 claims description 3
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 description 192
- 238000011282 treatment Methods 0.000 description 141
- 206010018910 Haemolysis Diseases 0.000 description 77
- 210000004027 cell Anatomy 0.000 description 48
- 230000008588 hemolysis Effects 0.000 description 46
- 201000010099 disease Diseases 0.000 description 41
- 238000002560 therapeutic procedure Methods 0.000 description 36
- 206010016256 fatigue Diseases 0.000 description 32
- 206010022822 Intravascular haemolysis Diseases 0.000 description 31
- 239000000902 placebo Substances 0.000 description 31
- 229940068196 placebo Drugs 0.000 description 31
- 230000002829 reductive effect Effects 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 29
- 210000001772 blood platelet Anatomy 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 26
- 201000001505 hemoglobinuria Diseases 0.000 description 21
- 208000007502 anemia Diseases 0.000 description 18
- 230000009089 cytolysis Effects 0.000 description 16
- 210000001995 reticulocyte Anatomy 0.000 description 16
- 102100022133 Complement C3 Human genes 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- 230000006872 improvement Effects 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 208000019505 Deglutition disease Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 229950003203 pexelizumab Drugs 0.000 description 12
- 230000010118 platelet activation Effects 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 208000004998 Abdominal Pain Diseases 0.000 description 11
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000010228 Erectile Dysfunction Diseases 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000004820 blood count Methods 0.000 description 10
- 201000001881 impotence Diseases 0.000 description 10
- 238000002203 pretreatment Methods 0.000 description 10
- 230000002411 adverse Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102000014702 Haptoglobin Human genes 0.000 description 7
- 108050005077 Haptoglobin Proteins 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 208000002815 pulmonary hypertension Diseases 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 5
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 230000024203 complement activation Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000010437 erythropoiesis Effects 0.000 description 5
- 230000003862 health status Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 5
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 4
- -1 Factor P Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 108010035766 P-Selectin Proteins 0.000 description 4
- 102100023472 P-selectin Human genes 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 4
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 4
- 229940127218 antiplatelet drug Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 108010089414 Anaphylatoxins Proteins 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 3
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 3
- 102100026553 Mannose-binding protein C Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700022034 Opsonin Proteins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010002601 epoetin beta Proteins 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000009589 serological test Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000003582 thrombocytopenic effect Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 206010008796 Chromaturia Diseases 0.000 description 2
- 108010028773 Complement C5 Proteins 0.000 description 2
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000009535 clinical urine test Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960005029 darbepoetin alfa Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108700040669 phosphatidylinositol glycan-class A Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- XGUFMAUYGBDFJS-UHFFFAOYSA-N 6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1h-naphthalene-8,2'-3h-1-benzofuran]-7'-carboxylic acid Chemical compound C1C(C(=CC(C=O)=C2C(O)=O)O)=C2OC21C1(C)CC(O)C(O)C(C)(C)C1CCC2C XGUFMAUYGBDFJS-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015871 Extravascular haemolysis Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035185 Hemolytic Congenital Anemia Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 206010060893 Hereditary haemolytic anaemia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 101710110798 Mannose-binding protein C Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027402 Mesenteric vein thrombosis Diseases 0.000 description 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028629 Myoglobinuria Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010030184 Oesophageal spasm Diseases 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 241001474791 Proboscis Species 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000032424 nitric oxide homeostasis Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000006995 pathophysiological pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/595.118 | 2006-11-08 | ||
| US11/595,118 US20070116710A1 (en) | 2004-02-03 | 2006-11-08 | Methods of treating hemolytic anemia |
| PCT/US2007/023623 WO2008069889A2 (en) | 2006-11-08 | 2007-11-08 | Methods of treating hemolytic anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0718830A2 true BRPI0718830A2 (pt) | 2014-02-04 |
Family
ID=39326944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0718830-7A BRPI0718830A2 (pt) | 2006-11-08 | 2007-11-08 | Métodos para tratar anemia hemolítica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070116710A1 (enExample) |
| EP (1) | EP2089058A2 (enExample) |
| JP (1) | JP2010509338A (enExample) |
| KR (1) | KR20090076960A (enExample) |
| AU (1) | AU2007328435B2 (enExample) |
| BR (1) | BRPI0718830A2 (enExample) |
| CA (1) | CA2669735A1 (enExample) |
| IL (1) | IL198320A0 (enExample) |
| MX (1) | MX2009004986A (enExample) |
| WO (1) | WO2008069889A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3022097C (en) | 2006-03-15 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| PT2698166E (pt) | 2006-10-10 | 2016-01-27 | Regenesance B V | Inibição do complemento para regeneração nervosa aprimorada |
| RU2010116245A (ru) * | 2007-09-24 | 2011-11-10 | Ноксон Фарма Аг (De) | НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| WO2009097120A1 (en) * | 2008-01-29 | 2009-08-06 | Celgene Corporation | Methods using immunomodulatory compounds for modulating level of cd59 |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| PT2328616E (pt) * | 2008-08-05 | 2015-08-26 | Novartis Ag | Composições e métodos para anticorpos dirigidos à proteína c5 do complemento |
| AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| MX2012005388A (es) | 2009-11-09 | 2012-07-23 | Alexion Pharma Inc | Reactivos y metodos para detectar globulos blancos pnh tipo ii y su identificacion como factores de riesgo para transtornos trombolicos. |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| SG11201403416TA (en) | 2011-12-21 | 2014-07-30 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| CN104145018B (zh) | 2012-01-10 | 2019-05-10 | 诺松制药股份公司 | 新型C5a结合性核酸 |
| EP3046581B1 (en) * | 2013-09-16 | 2020-04-01 | Children's Hospital Medical Center | Compositions and methods for treatment of hsct-associated thrombotic microangiopathy |
| KR102650420B1 (ko) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| WO2016117346A1 (en) | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| EP4374922A3 (en) | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| IT201600121482A1 (it) * | 2016-11-30 | 2018-05-30 | Univ Degli Studi Di Verona | Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme |
| KR101949891B1 (ko) | 2017-01-31 | 2019-02-19 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| US12037389B2 (en) | 2017-12-01 | 2024-07-16 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| US20210301004A1 (en) | 2018-08-01 | 2021-09-30 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| EP4003408A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| KR20240033090A (ko) | 2019-07-31 | 2024-03-12 | 에프. 호프만-라 로슈 아게 | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 |
| CN116406287A (zh) | 2020-04-16 | 2023-07-07 | 巴黎公共医疗救助机构 | 治疗由病毒引起的补体介导的障碍的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE60136656D1 (de) * | 2000-12-05 | 2009-01-02 | Alexion Pharma Inc | Rationell entworfene Antikörper |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
-
2006
- 2006-11-08 US US11/595,118 patent/US20070116710A1/en not_active Abandoned
-
2007
- 2007-11-08 EP EP07870863A patent/EP2089058A2/en not_active Withdrawn
- 2007-11-08 JP JP2009536309A patent/JP2010509338A/ja not_active Withdrawn
- 2007-11-08 BR BRPI0718830-7A patent/BRPI0718830A2/pt not_active Application Discontinuation
- 2007-11-08 WO PCT/US2007/023623 patent/WO2008069889A2/en not_active Ceased
- 2007-11-08 CA CA002669735A patent/CA2669735A1/en not_active Abandoned
- 2007-11-08 AU AU2007328435A patent/AU2007328435B2/en active Active
- 2007-11-08 KR KR1020097009296A patent/KR20090076960A/ko not_active Ceased
- 2007-11-08 MX MX2009004986A patent/MX2009004986A/es not_active Application Discontinuation
-
2009
- 2009-04-23 IL IL198320A patent/IL198320A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2089058A2 (en) | 2009-08-19 |
| MX2009004986A (es) | 2009-05-21 |
| WO2008069889A3 (en) | 2008-08-07 |
| KR20090076960A (ko) | 2009-07-13 |
| AU2007328435B2 (en) | 2013-03-07 |
| US20070116710A1 (en) | 2007-05-24 |
| CA2669735A1 (en) | 2008-06-12 |
| WO2008069889A2 (en) | 2008-06-12 |
| JP2010509338A (ja) | 2010-03-25 |
| WO2008069889A9 (en) | 2008-09-18 |
| AU2007328435A1 (en) | 2008-06-12 |
| IL198320A0 (en) | 2011-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0718830A2 (pt) | Métodos para tratar anemia hemolítica | |
| KR101197799B1 (ko) | 용혈성 질환을 치료하는 방법 | |
| ES2965283T3 (es) | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento | |
| EP3287142B1 (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| BR112016008409B1 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
| JP2018533592A (ja) | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 | |
| BR112020003207A2 (pt) | métodos de tratar um sujeito humano sofrendo de ou em risco de desenvolver doença do enxerto versus hospedeiro, hemorragia alveolar difusa e doença veno-oclusiva e de tratar, prevenir ou melhorar um ou mais sintomas neurológicos associados com a doença do enxerto versus hospedeiro ou microangiopatia trombótica associada com transplante de célula-tronco hematopoiética. | |
| AU2013206217A1 (en) | Methods of treating hemolytic anemia | |
| BR112018009311B1 (pt) | Uso de uma composição compreendendo uma quantidade de um anticorpo inibidor de masp-2 | |
| HK1094950B (en) | Method of treating hemolytic disease | |
| HK1175989A (en) | Method of treating hemolytic disease | |
| HK1175985A (en) | Method of treating hemolytic disease | |
| HK1175987A (en) | Method of treating hemolytic disease | |
| HK1175988A (en) | Method of treating hemolytic disease | |
| HK1175986A (en) | Method of treating hemolytic disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |